This study is for adult female patients that have been diagnosed with recurrent ovarian cancer. The purpose of this study is to evaluate whether therapy with tumor-infiltrating lymphocytes (TILs) enhances the immune response against cancer cells. Participants will undergo standard procedures such as blood collection for laboratory testing, physical exams, and imaging. In addition to standard of care treatment, TILs will be collected from the tumor, grown in a lab, and infused back into the body. Participants will also take three drugs (oral cyclophosphamide, bevacizumab, and pembrolizumab) following the TIL infusion. Participation in this study is expected to last approximately one year.